By Fineline Cube 
Advaccine Biotechnology (NEEQ: 874055) today disclosed a private placement offering of no more than 2,203,200 shares at RMB 136.17 per share, aiming to generate up to RMB 300 million in proceeds. The capital will be earmarked for expanding the company’s cutting‑edge microneedle manufacturing capabilities, accelerating R&D, and strengthening liquidity.
Allocation of Proceeds
| Use of Funds | Amount (RMB million) |
|---|---|
| Pilot‑scale & commercial microneedle workshops | 70 |
| R&D working capital | 100 |
| Routine operating expenses | 90 |
| Loan & bank borrowing repayment | 40 |
Technology Platforms & Product Pipeline
- Antigen Discovery Platform – Enables rapid identification of immunogenic targets across infectious and oncologic indications.
- Adjuvant Technology Platform – Enhances immune potency of vaccine candidates.
- Drug Delivery Platform – Focused on soluble microneedle technology for painless, at‑home administration.
Key Product Highlights
| Product | Status | Notable Milestone |
|---|---|---|
| Soluble Microneedle OTC Acne | FDA‑registered & approved in the U.S. | First microneedle acne product on the market |
| Soluble Microneedle OTC – Anti‑Wrinkle, Skin Anti‑Infection, Weight Loss | In development | Expanding OTC portfolio |
| ADV110 (RSV Vaccine) | Phase II completed | Met all primary endpoints; moving to Phase III |
| ADV2401 (Melanoma), ADV2402 (Breast Cancer), ADV2403 (Osteosarcoma) | Preclinical | Demonstrated significant tumor inhibition |
| ADV2104 (RRP Vaccine) | FDA‑RPDD | First therapeutic for Recurrent Respiratory Papillomatosis to receive Rare Pediatric Disease Designation |
Strategic Outlook
Advaccine’s capital raise will accelerate the transition from pilot to commercial scale, support high‑impact R&D, and fortify the company’s balance sheet. With FDA‑approved products and a robust pipeline, Advaccine is positioned to become a global leader in microneedle‑based vaccines and therapeutics.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech